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SUMMARY: The resistance phenotypes and genomic diversity of 185 Acinetobacter baumannii isolates
obtained from the intensive care unit (ICU) of a local teaching hospital in Kuala Lumpur from 2006 to
2009 were determined using antimicrobial susceptibility testing and pulsed-field gel electrophoresis
(PFGE). Antibiogram analyses showed that the isolates were fully resistant to b-lactam antimicrobials
and had high resistance rates to the other antimicrobial agents tested. However, the isolates were suscep-
tible to polymyxin B. Resistance to cefoperazone/sulbactam was only detected in strains isolated from
2007 to 2009. Some environmental isolates and an isolate from the hands of a healthcare worker (HCW)
had identical resistance profiles and PFGE profiles that were closely related to patient isolates. Cluster
analyses based on the PFGE profiles showed there was a persistent clone of endemic isolates in the ICU
environment. The transmission route from HCWs to fomites to patients, which caused a long-term in-
fection in the ICU of the University Malaya Medical Centre, was observed in this study. These data pro-
vide a better understanding of A. baumannii epidemiology within the hospital and the possible transmis-
sion routes. Knowledge of changes in the resistance rates of A. baumannii in our local hospital will im-
prove antimicrobial therapy.
Bacteria of the genus Acinetobacter are important op-
portunistic nosocomial pathogens that cause bactere-
mia, meningitis, and respiratory and urinary tract infec-
tions, particularly in immunocompromised patients (1).
Acinetobacter spp. are among the most common iso-
lates from intensive care units (ICUs) in most Malaysian
hospitals (2). Infection with Acinetobacter baumannii is
becoming a serious nosocomial problem, particularly in
the ICU. Most of the isolates are resistant to multiple
antimicrobial agents, and there is a current trend toward
increasing resistance to penicillins, b-lactams, ami-
noglycosides, fluoroquinolones, and carbapenems,
which are the drugs of choice for treatment of the infec-
tion (3,4). A. baumannii is able to acquire antibiotic
resistance genes and survive for days on fomites, both in
the hospital environment and on the hands of healthcare
workers (HCWs), which could lead to possible HCW-
fomites-patient transmission and the persistence of en-
demic A. baumannii strains in hospitals (5,6). Ap-
propriate identification of A. baumannii and discrimi-
nation among isolates during a nosocomial outbreak
could lead to a better understanding of the mode of
spread, thus enabling better control in an outbreak.
Macrorestriction analysis using pulsed-field gel elec-
trophoresis (PFGE) is considered the standard molecu-
lar method for epidemiological analyses of A. bauman-
nii (7).
In Malaysia, detailed information on the antimicrobi-
al resistance and genetic relationship of A. baumannii
strains is still lacking. Therefore, the aim of the present
study was to determine the antimicrobial susceptibility
and genetic relationship of nosocomial A. baumannii
isolates from the ICU at the University Malaya Medical
Centre (UMMC). Documentation of antibiograms and
DNA fingerprinting data of A. baumannii isolates is im-
portant to determine the prevalence of these isolates wi-
thin the hospital and their transmission in outbreaks in
order to provide better outbreak control and effectively
manage the patients' infections.
In this study, 185 A. baumannii isolates from the ICU
at UMMC were used for the analysis. Of these, 170
(92z) were clinical isolates obtained from different sites
in 2006 (n＝ 61), 2007 (n＝ 25), 2008 (n＝ 47), and
2009 (n＝ 37) (Table 1). The remaining 15 isolates were
from the environment and the hands of HCWs screened
in April, August, and September 2006 following the oc-
currence of increased incidence in March, June, July,
and September 2006. The isolates were confirmed as
A. baumannii by restriction analysis of amplified
ribosomal DNA as described by Dijkshoorn et al. (8)
(unpublished data).
The antimicrobial susceptibility of A. baumannii was
determined by the disk diffusion method in accordance
with the Clinical and Laboratory Standards Institute
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Table 1. Clinical A. baumannii isolates from different types of specimens from the intensive care units of the University Malaya Medical
Centre (2006 to May 2009)
Isolation
year
No. of isolates from different specimens
Total
T/sec T/asp Sputum Swab Catheter tip Blood Body fluid Nasal Urine Tissue
2006 25 2 2 8 10 4 7 1 1 1 61
2007 17 0 0 3 3 1 1 0 0 0 25
2008 21 0 2 7 5 3 6 1 1 1 47
2009 22 0 2 5 2 3 1 0 1 1 37
Total 85 2 6 23 20 11 15 2 3 3 170
T/sec, tracheal secretory; T/asp, tracheal aspirate.
guidelines (9). Escherichia coli ATCC 25922 was used as
the quality control organism. PFGE was performed by
ApaI (Promega, Madison, Wis., USA) digestion of
chromosomal DNA embedded in 1z SeaKem} Gold
Agarose (Cambrex Bio Science, Rockland, Maine,
USA) (10). Restriction fragments were obtained by
separation using a CHEF DR}III system (Bio-Rad,
Hercules, Calif., USA) with 0.5× TBE buffer for 26 h
at 149C with pulse times of 2–40 s. The PFGE profiles
were analyzed using BioNumerics version 6.0 software
(Applied Maths, Kortrijk, Belgium).
The present study shows that the A. baumannii iso-
lates had very high rates of resistance to the tested an-
timicrobial agents. All 170 clinical isolates of A. bau-
mannii showed 100z resistance to ampicillin, amoxicil-
lin/clavulanic acid, piperacillin/tazobactam, cefurox-
ime, ceftriaxone, cefoperazone, ceftazidime, and cefep-
ime. These isolates also exhibited high rates of resis-
tance to amikacin (78.8z), gentamicin (85.3z), am-
picillin/sulbactam (84.7z), cefoperazone/sulbactam
(34.7z), ciprofloxacin (99.4z), imipenem (96.5z),
meropenem (98.2z), and trimethoprim/sulfamethoxa-
zole (88.8z).
The rate of resistance to amikacin in the clinical iso-
lates decreased from 70.5z in 2006 to 52.0z in 2007;
however, the rate then increased to 91.5 and 97.3z in
2008 and 2009, respectively. Resistance to gentamicin
decreased from 91.8z in 2006 to 78.7z in 2008;
however, resistance increased slightly to 83.8z in 2009.
Similarly, resistance to trimethoprim/sulfamethoxazole
decreased to 88.0z in 2007 and 76.6z in 2008 com-
pared to 98.4z in 2006, then increased slightly to
89.2z in 2009. The clinical isolates had a high rate of
resistance to ampicillin/sulbactam throughout the 4-
year period (82.0z in 2006, 88.0z in 2007, 78.7z in
2008, and 94.6z in 2009). Although no cefoper-
azone/sulbactam-resistant isolates were observed in
2006, resistance was detected in 2007 (40.0z), and the
resistance rates increased to 55.3z in 2008 and 62.2z
in 2009. The environmental isolates exhibited 100z
resistance to cefoperazone, and had high resistance rates
to ampicillin (83.3z) and cefuroxime (61.1z). These
isolates had intermediate resistance rates, at varying
levels, to the other antimicrobial agents except cefoper-
azone/sulbactam. All the clinical and environmental
isolates of A. baumannii were fully susceptible to poly-
myxin B.
Twenty-seven different resistance profiles (R1–R27)
were observed. The predominant resistance profile, R11
(35.1z), comprised isolates resistant to all antimicrobi-
al agents except polymyxin B and cefoperazone/sulbac-
tam. Resistance profiles R23 to R27 comprised 7 non-
multidrug resistant (non-MDR) isolates from the en-
vironment and the hands of HCWs. Seven MDR en-
vironmental isolates shared a similar resistance profile
with the clinical isolates (R11).
PFGE analysis generated 98 profiles and the number
of DNA fragments ranged from 17 to 29 with sizes from
25.9 kb to 680.1 kb. A dendrogram based on represen-
tatives of each PFGE profile was generated (Fig. 1). On
the basis of 70z similarity, 8 clusters, A–H (5 isolates
or more in each cluster), with 27 clones were observed.
A clone was defined as a collection of bacterial isolates
independently isolated from different sources and at
different times that shared a similar PFGE profile (11).
Clones X, XVI, and XXVI were the predominant clones
observed in clusters D, G, and H, respectively.
Cluster A consisted of 3 different clones (I, II, and
III) with 92.9z similarity, and was comprised of 24 iso-
lates obtained in 2006. These 3 clones were closely relat-
ed, with less than 4 band differences (Fvalue＝
0.91–1.00). An isolate from the hands of a HCW
(ACIBA 47) and 3 MDR environmental isolates were
clustered together with the clinical isolates at more than
80z similarity. Clone X (2006 cefoperazone/sulbac-
tam-susceptible isolates) and clone XI (2007 cefoper-
azone/sulbactam-resistant isolates) were grouped in
cluster D with 5 DNA band differences (Fvalue＝
0.86–1.00).
Cluster G comprised 9 clones (XVI–XXIV) with
72.8z similarity. Clones XVI and XVII consisted of
2006 clinical isolates and 3 environmental MDR isolates
that were obtained in August 2006 with a similar
resistance profile (R11). Clones XVIII to XXIV consist-
ed of 2008 isolates. Cluster H comprised 3 clones
(XXV–XVII) of 28 isolates from 2009 with 84.7z simi-
larity and R11 and R13 resistance profiles. The non-
MDR environmental isolates were distinctly different
from the clinical isolates and had unique profiles.
In the present study, all the clinical A. baumannii iso-
lates exhibited high resistance to all the antimicrobial
agents tested except for polymyxin B. There was an
emergence of imipenem-resistant and amikacin-resistant
isolates, which were not found in a previous study from
the same hospital (12). A similar increase in the
resistance of A. baumannii isolates to imipenem and
amikacin from 1996 to 2006 was reported in Greece
(13). In addition, A. baumannii isolates (obtained in
2006–2007) from Singaporean hospitals were also highly
resistant to carbapenems (14). Routine use of the same
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Fig. 1. Dendrogram of representative A. baumannii isolates with 27 different resistance profiles using the unweight-
ed pair group arithmetic means methods (UPGMA). The dotted vertical line indicates 70z similarity.
antimicrobial agents for treatment might have con-
tributed to the selective pressure for resistance build-up.
Williams (15) reported that addition of sulbactam,
tazobactam, and clavulanic acid as b-lactamase inhibi-
tors could increase the susceptibility of A. baumannii to
penicillins and cephalosporins. However, in this study,
the isolates were 100z resistant to both amoxicillin
clavulanic and piperacillin/tazobactam, and had a high
resistance to ampicillin/sulbactam (84.1z). Although
the combination of cefoperazone and sulbactam were
effective against A. baumannii isolated in 2006, there
was evidence of diminished effectiveness, since cefoper-
azone/sulbactam-resistant isolates were detected in the
period 2007–2009.
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Ballow and Schentag (16) reported that replacement
with piperacillin plus an aminoglycoside resulted in
recovery of penicillin susceptibility and reduction of
ceftazidime resistance in cephalosporin resistant En-
terobacter cloacae isolates. In our study, substituting
cefoperazone/sulbactam for therapeutic treatment
might have decreased resistance to aminoglycosides and
trimethoprim/sulfamethoxazole. However, increased
use of cefoperazone/sulbactam might have resulted in
the increased resistance observed in 2007. Therefore,
properly scheduled antibiotic class changes are needed
to select appropriate drugs for treatment. Polymyxins
have been used as the therapeutic option for treatment
of MDR A. baumannii infections (13,17); however,
there have been reports of polymyxins-resistant A. bau-
mannii in the US (18) and Korea (19). Fortunately, the
A. baumannii isolates in our hospital remain sensitive to
polymyxin B.
Isolates in this study with PFGE profiles AC034 and
AC063 were believed to be endemic in the ICU area
throughout the year of 2006. An indication of an en-
demic clone of A. baumannii isolates in the ICU at
UMMC was the observed persistence of environmental
and multiple subtypes throughout the study period. An
isolate from the hands of HCW had a closely related
PFGE profile and similar resistance profile to isolates
from patients, suggesting likely transmission from
HCWs to patients via the hands. The transmission route
among HCW-fomites-patient in the ICU at UMMC
may have occurred; however, the direction was
unknown. Careful hand hygiene and environmental
cleaning should contribute to the successful control of
MDR A. baumannii outbreaks in ICUs (20).
In conclusion, A. baumannii isolates from the ICU at
UMMC from 2006 to 2009 had high resistance rates to
the majority of antimicrobials commonly used in
hospitals. Only polymyxin B remains effective for the
treatment of infections caused by A. baumannii. PFGE
analysis confirmed a persistent clone of MDR A. bau-
mannii in the ICU environment, which might have led
to an increased incidence of infection throughout the
year of 2006. Hence, proper management and careful
selection of antimicrobial agents for the treatment of A.
baumannii infection is important for preventing the
build-up of resistance.
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